Research
Hormonal
Restoring Insulin-like Growth Factor 1 (IGF-I) levels or blocking Myostatin (Mstn) production can prevent or reverse glucocorticoid-induced muscle atrophy.
Current research suggests that therapies targeting IGF-I or Myostatin could protect muscle during steroid treatment. However, these are not yet standard clinical practices for all patients. Focus on maintaining protein intake and resistance training as foundational strategies while consulting your doctor about the specific risks and benefits of your steroid regimen.
StrongSupportsHIGH confidence
Restoration of IGF-I may provide a strategy to reverse the catabolic effects of glucocorticoid excess... inhibition of Mstn may provide another strategy to reverse the catabolic effects of glucocorticoid excess.
Why this rating
Supported by multiple in vitro, in vivo, and transgenic mouse studies cited in the review.
Source
Mechanisms of glucocorticoid-induced myopathy
O Schakman et al. · Journal of Endocrinology · 2008
DOI 10.1677/joe-07-0606
narrative_reviewCited 499×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →